Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Combination with TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Chemotherapy in Patients with Stage III or IV Unresectable Pancreatic Cancer.

NCT03252808 is registered in ClinicalTrials.gov with Takara Bio Inc. as lead sponsor.

NCT NCT03252808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03252808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Combination with TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Chemotherapy in Patients with Stage III or IV Unresectable Pancreatic Cancer.
Lead sponsor
Takara Bio Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 25, 2017
Completion date
March 31, 2035
Enrollment
36 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer stage iii, pancreatic cancer stage iv